In a significant move aimed at strengthening ethical medical practices, the Central Government has banned the entry of medical representatives (MRs) into government hospitals across the country. The directive, issued by the Directorate General of Health Services (DGHS) under the Ministry of Health and Family Welfare, prohibits pharmaceutical company representatives from directly meeting doctors within hospital premises.
According to the official order, all central government hospitals have been instructed to strictly enforce the ban and ensure that medical representatives are not allowed inside hospital premises. Authorities have emphasized that the move is intended to curb unethical practices and eliminate the long-standing nexus between pharmaceutical companies and doctors, which could influence prescription behaviour.
The government has clarified that pharmaceutical companies can still share information regarding new drugs, treatments, or medical advancements but only through digital means such as email or official online platforms. Direct interaction between doctors and medical representatives has been completely discouraged under the new rules.
Officials have stated that one of the key reasons behind the decision is to ensure that doctors devote their full time and attention to patient care rather than promotional meetings. Reports suggest that frequent visits by medical representatives often disrupted hospital functioning and reduced the time available for treating patients, particularly in overcrowded government facilities.
Hospital authorities have been directed to issue strict internal instructions and ensure full compliance with the order. Heads of institutions are also required to monitor implementation and submit reports to the DGHS, indicating the actions taken to enforce the ban.
The Centre’s decision marks a major step toward promoting transparency, accountability, and patient-centric care in public healthcare institutions. By limiting direct interaction between pharmaceutical companies and doctors, the government aims to ensure that medical decisions are based solely on clinical evidence and patient needs rather than commercial interests.